Annals of Oncology 8:143-148, 1997
© 1997 European Society for Medical Oncology
research-article |
BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
1Klinik I für Innere Medizin. Universität Köln Germany
2Medizinische Klinik & Poliklinik. Universitat Homburg Germany
3Medizinische Klinik A. Universität Münster Germany
4Medizinische Klinik & Poliklunk. Universität Göttingen Germany
5Institut für Medizinische Informark, Statistik und Epidemologie, Universität Leipzig Germany
Correspondence to: Volker Diehl, MD Hodgkin-Studiensekretariat Klinik I für Innere Medizin Universität zu Köln 50924 Köln Germany
PURPOSE:: At present, treatment results for patients with advanced-stage Hodgkin's disease remain unsatisfactory. Standard chemotherapy M(C)OPP (nitrogen mustard (cyclophosphamide), vincristine, procabazine, and prednisone), ABVD (adriamycine, bleomycine, vinblastine, and dacarbacine) or M(C)OPP/ABVD +/- radiotherapy fail to achieve long-term complete remission in 35% to 50% of these patients. The BEACOPP (bleomycin, etoposide, adriamycine, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen was developed to improve treatment results by dose intensification achieved by reduced duration of treatment (time intensification) and addition of etoposide.
PATIENTS AND METHODS:: Thirty untreated patients with advanced Hodgkin's disease stage IIB-IV according to the Ann Arbor classification were treated with the time intensified BEACOPP regimen. Each patient was scheduled to receive eight cycles of chemotherapy with consolidating radiotherapy to sites of initial bulk disease and to residual tumor remaining after chemotherapy.
RESULTS:: All patients were evaluable for assessment of toxicity, treatment response, freedom from treatment failure (FFTF) and survival (SV). Of 30 treated patients, 29 patients received the intended eight cycles of BEACOPP. One patient, in clinical CR, terminated the chemotherapy at his own request after six cycles and is at this time, 48 months after the end of treatment, in complete remission. Toxicity was tolerable with WHO grade 3/4 leucopenia in 28% of chemotherapy cycles and one severe (WHO grade 3) infection. No treatmentrelated death occurred. Cycles could generally be given on schedule. Complete remission (CR) was achieved in all but two patients (93%). At present, only one patient has relapsed. At a median follow-up of 40 months, FFTF-rate is 89% (lower confidence limit: 80%). One patient died due to progressive disease.
CONCLUSION:: The BEACOPP regimen is feasible at moderate hematopoeitic toxicity. With a FFTF-rate of 89% at a median follow-up of 40 months, the treatment results are very encouraging. A prospective randomised trial has been initiated to compare the BEACOPP regimen with the standard COPP/ABVD regimen in advanced-stage Hodgkin's disease.
BEACOPP, chemotherapy, Hodgkin'sdisease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A.E. van der Kaaij, N. Heutte, N. Le Stang, J. M.M. Raemaekers, A. H.M. Simons, P. Carde, E. M. Noordijk, C. Ferme, J. Thomas, H. Eghbali, et al. Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., July 1, 2007; 25(19): 2825 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Ansell and J. O. Armitage Management of Hodgkin Lymphoma Mayo Clin. Proc., March 1, 2006; 81(3): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Gobbi, C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, et al. MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors Clin. Cancer Res., January 15, 2006; 12(2): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Engert, V. Ballova, H. Haverkamp, B. Pfistner, A. Josting, E. Duhmke, K. Muller-Hermelink, and V. Diehl Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group J. Clin. Oncol., August 1, 2005; 23(22): 5052 - 5060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ballova, J.-U. Ruffer, H. Haverkamp, B. Pfistner, H. K. Muller-Hermelink, E. Duhmke, P. Worst, M. Wilhelmy, R. Naumann, M. Hentrich, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) Ann. Onc., January 1, 2005; 16(1): 124 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Connors Hodgkin's Lymphoma: The Hazards of Success J. Clin. Oncol., September 15, 2003; 21(18): 3388 - 3390. [Full Text] [PDF]
|
|
|
|
|
|
M. Federico, M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. Colombat, S. Luminari, F. Fabbiano, et al. High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2320 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Diehl, J. Franklin, M. Pfreundschuh, B. Lathan, U. Paulus, D. Hasenclever, H. Tesch, R. Herrmann, B. Dorken, H.-K. Muller-Hermelink, et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease N. Engl. J. Med., June 12, 2003; 348(24): 2386 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sieber, H. Bredenfeld, A. Josting, T. Reineke, U. Rueffer, T. Koch, R. Naumann, F. Boissevain, P. Koch, P. Worst, et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin's Lymphoma: Results of a Pilot Study of the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., May 1, 2003; 21(9): 1734 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Horning, R. T. Hoppe, S. Breslin, N. L. Bartlett, B. W. Brown, and S. A. Rosenberg Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial J. Clin. Oncol., February 1, 2002; 20(3): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connors, E. M. Noordijk, and S. J. Horning Hodgkin's Lymphoma: Basing the Treatment on the Evidence Hematology, January 1, 2001; 2001(1): 178 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takenaka, C. Mikuni, A. Miura, T. Sasaki, H. Suzuki, T. Hotta, M. Hirano, S. Fukuhara, H. Sugiyama, K. Nasu, et al. Alternating Combination Chemotherapy C-MOPP (Cyclophosphamide, Vincristine, Procarbazine, Prednisone) and ABVd (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) in Clinical Stage II-IV Hodgkin's Disease: a Multicenter Phase II Study (JCOG 8905) Jpn. J. Clin. Oncol., March 1, 2000; 30(3): 146 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Sweetenham, A. M. Carella, G. Taghipour, D. Cunningham, R. Marcus, A. D. Volpe, D. C. Linch, N. Schmitz, and A. H. Goldstone High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation J. Clin. Oncol., October 1, 1999; 17(10): 3101 - 3109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Andrieu, U. Yilmaz, P. Colonna, M. Loeffler, O. Brosteanu, and D. Hasenclever MOPP Versus ABVD and Low-Dose Versus High-Dose Irradiation in Hodgkin's Disease at Intermediate and Advanced Stages: Analysis of a Meta-Analysis by Clinicians J. Clin. Oncol., February 1, 1999; 17(2): 730 - 730. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]
|
|
|
|
|
|
H. Tesch, V. Diehl, B. Lathan, D. Hasenclever, M. Sieber, U. Ruffer, A. Engert, J. Franklin, M. Pfreundschuh, K.P. Schalk, et al. Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group Blood, December 15, 1998; 92(12): 4560 - 4567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Gobbi, C. Pieresca, M. L. Ghirardelli, N. DiRenzo, M. Federico, F. Merli, E. Iannitto, V. Pitini, G. Grignani, A. Donelli, et al. Long-Term Results From MOPPEBVCAD Chemotherapy With Optional Limited Radiotherapy in Advanced Hodgkin's Disease Blood, April 15, 1998; 91(8): 2704 - 2712. [Abstract] [Full Text] [PDF]
|
|